On this page
Evidence dossier
The report behind the claim
The authors reported improved closure-related and functional findings in the animal model. The paper does not establish a nonsurgical treatment for a human bowel fistula.
Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint.
- Design
- Experimental animal investigation with the intervention and outcomes specified in the indexed abstract.
- Participants or model
- Rats with surgically created duodenocolic fistulas
- Endpoint
- Vessel presentation, leakage, tissue defects, adhesions and passage
- Finding on record
- The authors reported improved closure-related and functional findings in the animal model.
- Limits of inference
- The paper does not establish a nonsurgical treatment for a human bowel fistula.
The experiment in view
The study used rats with surgically created duodenocolic fistulas. Its principal measures were vessel presentation, leakage, tissue defects, adhesions and passage. The authors reported improved closure-related and functional findings in the animal model.
Reading the result closely
An internal connection between two bowel segments is not the same injury as an external skin opening. Leakage, obstruction and tissue appearance each answer a separate question. Treating every fistula paper as a replication of the same endpoint would conceal the anatomical differences.
The boundary of the finding
The paper does not establish a nonsurgical treatment for a human bowel fistula.
Related evidence, kept separate
BPC-157 in a colon-to-bladder fistula model examines leakage, defects, adhesions and bowel passage. Here, the measured endpoint was vessel presentation, leakage, tissue defects, adhesions and passage. Those outcomes belong to separate experiments; one is not a replication or a human confirmation of the other. Compare that distinction with the Drug-induced cystitis in rats is not the twelve-patient bladder study appraisal.
On the record
The documents supporting this report.